What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
出版年份 2020 全文链接
标题
What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 22, Issue S1, Pages 55-68
出版商
Wiley
发表日期
2020-04-08
DOI
10.1111/dom.13965
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dapagliflozin and Cardiovascular Mortality and Disease Outcomes in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study
- (2019) Anna Norhammar et al. DIABETES OBESITY & METABOLISM
- Analysis from the EMPA-REG OUTCOME® trial indicate empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
- (2019) Gert J. Mayer et al. KIDNEY INTERNATIONAL
- Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis
- (2019) Hillel Sternlicht et al. CURRENT HYPERTENSION REPORTS
- Mineralocorticoid Antagonism and Diabetic Kidney Disease
- (2019) Yuliya Lytvyn et al. Current Diabetes Reports
- A Big Win for Diabetic Kidney Disease: CREDENCE
- (2019) David Z.I. Cherney et al. Cell Metabolism
- A safety update on sodium glucose co‐transporter 2 inhibitors
- (2019) David Fitchett DIABETES OBESITY & METABOLISM
- Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation between sglt2 inhibitors and dpp4 inhibitors using a supervised machine learning algorithm (profile study): A Retrospective analysis of a japanese commercial medical database
- (2019) Fang Liz Zhou et al. DIABETES OBESITY & METABOLISM
- Molecular regulation of the renin–angiotensin system by sodium–glucose cotransporter 2 inhibition in type 1 diabetes mellitus
- (2019) Chantal Kopecky et al. DIABETOLOGIA
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
- (2019) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
- (2019) Kengo Kidokoro et al. CIRCULATION
- Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure
- (2019) Javed Butler et al. Circulation-Heart Failure
- The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
- (2019) Daniël H. van Raalte et al. DIABETES CARE
- Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
- (2019) Bruce A. Perkins et al. DIABETES CARE
- Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
- (2019) Brendon L. Neuen et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- SGLT2 inhibitors’ interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn
- (2019) Michaël J.B. van Baar et al. KIDNEY INTERNATIONAL
- Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
- (2019) Vlado Perkovic et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
- (2019) Pedro Monteiro et al. AGE AND AGEING
- Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
- (2019) Toshiaki Ohkuma et al. DIABETES OBESITY & METABOLISM
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus
- (2019) Yuichiro Ito et al. Diabetes Therapy
- Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes
- (2018) Sharon C. Peacock et al. ANESTHESIA AND ANALGESIA
- Sick-Day Medication List
- (2018) Canadian Journal of Diabetes
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
- (2018) Chantal Mathieu et al. DIABETES CARE
- Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes
- (2018) Petter Bjornstad et al. DIABETES CARE
- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER
- (2018) Patrick B. Ryan et al. DIABETES OBESITY & METABOLISM
- Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
- (2018) Claire C. J. Dekkers et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
- (2018) Paola Fioretto et al. DIABETES OBESITY & METABOLISM
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
- (2018) Subodh Verma et al. DIABETOLOGIA
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
- (2018) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Acute renal outcomes with SGLT-2 inhibitors - real world data analysis
- (2018) Avivit Cahn et al. DIABETES OBESITY & METABOLISM
- Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study
- (2018) Gian Paolo Fadini et al. DIABETES OBESITY & METABOLISM
- Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
- (2018) Habib Yaribeygi et al. DRUG DISCOVERY TODAY
- Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials
- (2018) Daniël H. van Raalte et al. KIDNEY INTERNATIONAL
- Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
- (2018) Hsien-Yen Chang et al. JAMA Internal Medicine
- Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease
- (2018) Kazuo Kobayashi et al. Diabetes & Vascular Disease Research
- Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
- (2018) Lindsay E. Clegg et al. DIABETES CARE
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
- (2018) Paresh Dandona et al. DIABETES CARE
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
- (2018) Julio Rosenstock et al. DIABETES CARE
- Sodium transport in diabetes: two sides to the coin
- (2018) Julie A. Lovshin et al. Nature Reviews Nephrology
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
- (2018) Takashi Kadowaki et al. Journal of Diabetes Investigation
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
- (2017) Michael Fralick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
- (2017) David Cherney et al. PLoS One
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition
- (2017) Subodh Verma et al. JAMA Cardiology
- Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2017) Subodh Verma et al. CIRCULATION
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
- (2017) Jiali Liu et al. Scientific Reports
- No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?
- (2016) Bruce A. Perkins et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists
- (2016) David Z.I. Cherney et al. CIRCULATION
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies
- (2016) Petter Bjornstad et al. Current Diabetes Reports
- New and old agents in the management of diabetic nephropathy
- (2016) Yuliya Lytvyn et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
- (2016) David Cherney et al. DIABETOLOGIA
- Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis
- (2016) Harindra Rajasekeran et al. KIDNEY INTERNATIONAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
- (2015) Marko Škrtić et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
- (2015) Bruce A. Perkins et al. PLoS One
- Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?
- (2014) David Z.I. Cherney et al. Canadian Journal of Diabetes
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial
- (2014) Bruce A. Perkins et al. DIABETES CARE
- Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
- (2014) Marko Škrtić et al. DIABETOLOGIA
- Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
- (2014) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Genital Mycotic Infections in Patients With Diabetes
- (2013) Paul Nyirjesy et al. POSTGRADUATE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started